In the current case study, investigators performed a genetic analysis of FXN gene intron 1 in which the parental and sibling’s DNA samples were extracted from peripheral blood using an automatable extraction method. Duplication/deletion analysis of FXN gene was also conducted using the Multiplex Ligation-dependent Probe Amplification Probemix P316-B4 Recessive Ataxias kit (MRC Holland, Amsterdam, The Netherlands). In the breakpoints of the deletion whole genome sequencing, using xGen DNA Library Prep Kit EZ (Integrated DNA Technologies, Iowa, USA), researchers observed that the deletion spanned 151,09 kb (chr9:71,510,734–71,661,828) and included exons 9–16 of the PIP5K1B gene (NM_003558.4), the entire PRKACG gene (NM_002732.4) and exons 1–2 of the FXN gene (NM_000144.5).
“We report a novel intragenic deletion that includes the 5’UTR upstream region and exons 1 and 2 of the FXN gene. This unreported deletion is predicted to eliminate the start codon, and consequently no protein will be produced. Loss of function is a known disease-causing mechanism for this condition, so the deletion was classified as pathogenic,” Padró-Miquel et al noted.1
Investigators observed a 50% reduction in the relative peak height of the probes corresponding to FXN exons 1 and 2. In addition, the authors observed a normal diploid dosage in the probes corresponding to FXN exons 3, 4 and 5. Overall, the authors concluded that the mother carried an allele of 9 GAA repeats and a deletion spanning the 5’UTR as well as exons 1–2 of FXN gene. Additionally, authors noted that the proband had an expansion inherited from the father and a deletion encompassing 5’UTR and exons 1–2 of FXN gene of maternal origin. As a noted limitation with the methods used in this study, the size of the expanded allele could not be determined. The study authors also recommended to either conduct a paternity test or verify the size of the shared allele through alternative means to confirm the shared allele between the father and the son.
“Parental sample testing was essential in the case presented, as we were able to detect that the mother and the proband were carriers of an intragenic deletion not reported before. This finding also has implications for other family members who could be possible carriers of the deletion and taking into account the elevated carrier frequency of FA, they could be at high risk of having children with FA,” Padró-Miquel et al noted.1 “This is the reason why we suggest that, if available, parental sample testing should be performed and not assume that parents are obligate carriers of an expansion since it is possible that deletions may be more prevalent than it was initially thought.”
REFERENCES
1. Aguilera C, Esteve-Garcia A, Casasnovas C, et al. Novel intragenic deletion within the FXN gene in a patient with typical phenotype of Friedreich ataxia: may be more prevalent than we think?. BMC Med Genomics. 2023;16(1):312. Published 2023 Dec 1. doi:10.1186/s12920-023-01743-0